ARCHIVED - Public Health Agency of Canada

Name of Horizontal Initiative: Federal Initiative to Address HIV/AIDS in Canada (FI)

Name of lead department(s): Public Health Agency of Canada (the Agency)

Lead department program activities: Disease and Injury Prevention and Mitigation; Surveillance and Population Health Assessment; Science and Technology for Public Health

Start date of the Horizontal Initiative: January 13, 2005

End date of the Horizontal Initiative: Ongoing

Total federal funding allocation (start to end date): N/A – there is no fixed end date for this horizontal initiative

Description of the Horizontal Initiative (including funding agreement): The FI strengthens domestic action on HIV and AIDS, builds a coordinated Government of Canada approach, and supports global health responses to HIV and AIDS. It focuses on prevention and access to diagnosis, care, treatment and support for those populations most affected by HIV and AIDS in Canada - people living with HIV and AIDS, gay men, Aboriginal people, people who use injection drugs, federal inmates, youth, women, and people from countries where HIV is endemic. The FI also supports and strengthens multi-sector partnerships to address the determinants of health. It supports collaborative efforts to address factors which can increase the transmission and acquisition of HIV including sexually transmitted infections (STI) and also addresses co-infection issues with other infectious diseases (e.g., Hepatitis C and tuberculosis) from the perspective of disease progression and morbidity in people living with HIV and AIDS. People living with and vulnerable to HIV and AIDS are active partners in shaping policies and practices affecting their lives.

Shared outcome(s): The FI's shared outcomes are: preventing the acquisition and transmission of new infections; improving the quality of life for those at risk for and living with HIV and AIDS; contributing to the global effort to reduce the spread of HIV and AIDS and mitigate its impact, and contributing to the strategic outcomes of partner departments and agencies.

Governance structure(s): The Responsibility Centre Committee (RCC) is the governance body for the FI. It comprises directors of the 10 Responsibility Centres which receive funding through the FI. Led by the Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and ensures that evaluation and reporting requirements are met.

The  Agency is the federal lead for issues related to HIV and AIDS in Canada responsible for overall coordination, communications, social marketing, reporting, evaluation, national and regional programs, policy development, surveillance and laboratory science.

 Health Canada (HC) supports community-based HIV and AIDS education, capacity-building, and prevention for First Nations on-reserve and Inuit communities south of the 60-degree parallel and provides leadership on international health policy and program issues.

As the Government of Canada's agency for health research, the  Canadian Institutes of Health Research (CIHR) sets priorities for and administers the extramural research program.

 Correctional Service of Canada (CSC), an agency of the  Public Safety Portfolio, provides health services (including services related to the prevention, diagnosis, care and treatment of HIV and AIDS) to offenders sentenced to two years or more.

Planning Highlights: Recommendations from the  implementation evaluation of the FI continue to be implemented. Performance measurement and performance information systems, and FI RCC governance will be strengthened.

Federal Partner: The Agency

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
1.1 Science and Technology for Public Health	HIV/AIDS Reference Testing	Ongoing	$1.7M	ER 1
1.2 Surveillance and Population Health Assessment	Surveillance of Infectious Disease	Ongoing	$5.1M	ER 2
1.5 Disease and Injury Prevention and Mitigation	Infectious Disease Prevention and Control & Community Associated Infections	Ongoing	$35.6M	ER 3.1  ER 3.2  ER 3.3
Total Agency			$42.4M

Expected Results:

ER 1: Public health decisions and interventions by public health officials are supported by timely and reliable and accredited reference service testing.

ER 2: Establish prevalence of Sexually Transmitted and Blood-borne Infections (STBBI), patterns of risk and health behaviours and monitor trends among men who have sex with men and street youth in Canada through the support of national survey data collection, analysis, interpretation, transfer and exchange for M-Track and E-SYS.

ER 3.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease, as indicated by:

1. the number and type of evidence-based information products, including three population-specific reports, an HIV prevention framework, HIV counselling and testing guidelines, the Canadian Guidelines on Sexually Transmitted Infections, Canadian Sexual Health Education Guidelines information products, interdepartmental pilot projects to address HIV and the determinants of health, augmented HIV case reporting, targeted epidemiological studies, improved knowledge and characterization of HIV strains in Canada, and findings from the study of HIV and AIDS funding programs' structure;
2. ongoing support and guidance provided to partners, including the number and type of knowledge and awareness activities and products, and processes to develop funding proposals aligned with public health priorities; 
3. project data on number of presentations and workshops and their reach; and
4. project data on increases in knowledge of HIV transmission and risk factors among target populations.

ER 3.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS, as indicated by:

1. coordinated approaches to data collection and dissemination, enhanced collaboration with key stakeholders in the response to HIV and AIDS, and STI's, including committees, partnerships and collaborative documents;
2. focussed advisory and coordination agendas that link to FI expected results;  
3. enhanced engagement of community organisations in the response to HIV and AIDS and the factors that impact those affected and at risk for infection, the number of invitations to submit applications for specific types of activities and the number of funded project proposals;
4. project data on number and type of partnerships and their results; 
5. project data on improved access to health and social services; and
6. on-going guidance provided to partners.

ER 3.3: Increased individual and organizational capacity to address HIV and AIDS, as indicated by:

1. sustained support to community-based organizations, including the number of projects funded and funds provided to community-based funding;
2. number of projects in which target populations contribute to management and delivery of projects;
3. number and type of capacity building activities for non-governmental and community-based organizations;
4. project data on actions to improve access to health and social services; and
5. project data on number of volunteers and volunteer hours.

Federal Partner: HC

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
International Health Affairs	Global Engagement	Ongoing	$1.4M	ER 1.1  ER 1.2
First Nations and Inuit Health Programming and Services	Bloodborne Diseases and Sexually Transmitted Infections—HIV/AIDS	Ongoing	$4.0M	ER 2.1  ER 2.2
Total HC			$5.4M

Expected Results:

ER 1.1: Increased Canadian engagement and leadership in the global context through exchanging best practices with global partners to inform global and domestic policies on HIV and AIDS. This will be achieved by supporting the development and dissemination of two documents, and through increased dialogue and engagement with stakeholders and other Government of Canada departments by engaging in three global forums to share expertise and influence policies.

ER 1.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS through provision of support to five formal advice documents to inform global collaboration on HIV and AIDS and policy coherence across federal government's global activities on HIV and AIDS.

ER 2.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease through the production of:

1. a companion reference manual for nursing practice specific to Aboriginal communities on-reserve and Inuit populations to complement the Canadian Guidelines on Sexually Transmitted Infections; and
2. a training tool to upgrade nursing skills on HIV, AIDS and STBBI.

ER 2.2: Increased individual and organizational capacity to address HIV and AIDS, as indicated by:

1. a gap analysis report on HIV and AIDS-STBBI - related services delivered by community nurses at health facilities on reserve;
2. the number of community researchers attending a research proposal writing workshop;
3. the number of First Nations and Inuit health nurses receiving training on HIV and AIDS and related health issues; and
4. the number of educational workshops for First Nations and Inuit health nurses.

Federal Partner: CIHR

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
HIV and AIDS Research Projects and Personnel Support	HIV and AIDS Research Initiative	Ongoing	$21.3M	ER 1.1  ER 1.2
Total CIHR			$21.3M

Expected results:

ER 1.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease through the funding of high-quality research and knowledge translation grants in HIV and AIDS. This will be achieved through the ongoing development and administration of strategic research funding programs.

ER 1.2: Increased individual and organizational capacity for HIV and AIDS research through the funding of high-quality capacity-building grants and awards in HIV and AIDS. This outcome is achieved through the ongoing development and administration of strategic research capacity-building funding programs.

Federal Partner: CSC

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Custody	Institutional Health Services Public Health Services	Ongoing	$4.2M	ER 1.1  ER 1.2
Total CSC			$4.2M

Expected results:

ER 1.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease, as indicated by the percentage of federal offenders who indicate improved general knowledge of HIV and AIDS after attending CSC's Peer Education Course.

ER 1.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS, as indicated by collaborative partnerships with the Federal/Provincial/Territorial Heads of Corrections Working Group on Health and CSC's Community Consultation on Public Health.

Total Allocation For All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2010–11
Ongoing	$73.3M

Results to be achieved by non-federal partners (if applicable): N/A

Contact information:
Stephanie Mehta
100 Eglantine Drive
Ottawa, ON K1A 0K9

Name of Horizontal Initiative: Preparedness for Avian and Pandemic Influenza

Name of lead department(s): Public Health Agency of Canada (the Agency)

Lead department program activities:  Public Health Preparedness and Capacity; Disease and Injury Prevention and Mitigation; Surveillance and Population Health Assessment; Science and Technology for Public Health; Regulatory Enforcement and Emergency Response

Start date of the Horizontal Initiative: Late 2006

End date of the Horizontal Initiative: Ongoing

Total federal funding allocation (start to end date): $600M (2009-10 RPP stated $617M based on a cash basis whereas the 2010-11 figure is now based on an accrual basis)

Description of the Horizontal Initiative (including funding agreement): Canada is facing two major, inter-related animal and public health threats: the potential spread of avian influenza (AI) virus (i.e., H5N1) to wild birds and domestic fowl in Canada and the potential for a human-adapted strain to arise resulting in human-to-human transmission potentially triggering a human influenza pandemic. A coordinated and comprehensive plan to address both avian and pandemic influenza is required.

In 2006, the Health Portfolio received $405M (2009-10 RPP stated $422M based on a cash basis whereas the 2010-11 figure is now based on an accrual basis) over five years to improve preparedness for avian and pandemic influenza. The bulk of the initiatives are ongoing. Initiatives are being launched in the areas of vaccines and antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. Efforts will also be undertaken to fill gaps in on-reserve planning and preparedness and enhance federal capacity to deal with an on-reserve pandemic.

Under the umbrella of “Preparing for Emergencies”, in 2006 the Canadian Food Inspection Agency (CFIA) obtained $195M to be spent over five years to enhance Canada's state of AI preparedness. CFIA funding was later reduced to $170M over five years as a result of strategic review. Canada's Avian Influenza Working Group was established in 2006 to update policies, protocols, operating procedures, and systems to enhance Canada's state of preparedness through collaborations and partnership in five strategies and processes—prevention and early warning, emergency preparedness, emergency response, recovery, and communications

Shared outcome(s): These initiatives will allow the federal government to strengthen Canada's capacity to prevent and respond to immediate animal health and economic impacts of AI while increasing preparedness for a potential pandemic.

Greater protection for Canadians will come about with improved vaccines and antivirals, improved emergency preparedness, and increased surge capacity to better address peak periods as well as through critical science and regulation processes. There will be enhanced on-reserve planning and preparedness and improved federal capacity to deal with an on-reserve pandemic.

Response speed and effectiveness will be enhanced through prevention and early warning measures, risk communication and inter-jurisdictional collaboration

Governance structure(s): In January 2008, the  Agency,  Health Canada (HC), the  Canadian Institutes of Health Research (CIHR), and the  Canadian Food Inspection Agency (CFIA) finalized the Avian and Pandemic Influenza Preparedness Interdepartmental/Agency Governance Agreement. The primary scope of the Agreement is the management of specific horizontal issues and/or initiatives stemming from the $1B for avian and pandemic influenza preparedness emanating from Budget 2006. Ministerial accountability is not altered by this agreement and departments and agencies maintain their responsibility to manage their mandated areas and the funds entrusted to them.

The Agreement is supported by a structure that falls within the auspices of the Deputy Minister's Committee on Avian and Pandemic Influenza Planning (CAPIP). The implementation of the Agreement is led by the Avian and Pandemic Influenza Assistant Deputy Ministers Governance (API ADM Governance) Committee focusing on the implementation of the initiatives funded through Budget 2006. 

The API ADM Governance Committee provides strategic direction and oversight monitoring. It authorizes and facilitates overview reporting to the Treasury Board Secretariat. Members of this committee ensure support for the initiatives in their departments or agencies. The API ADM Governance Committee keeps the Committee of ADMs under the CAPIP process informed of its activities through cross membership.

An Avian and Pandemic Influenza Operations Directors General (APIO DG) Committee supports the API ADM Governance Committee, makes recommendations to it and oversees the coordination of the deliverables of the committee's mandate. The APIO DG committee keeps the DG Steering Committee under the CAPIP process informed of its activities through cross membership. The APIO DG Committee is chaired by PHAC and CFIA members, and its membership includes Director General-level representatives from HC and CIHR and chairs of previously-established working groups.

Working groups are established for areas that cross departmental/agency activities. Working groups report to the API ADM Governance Committee through the APIO DG Committee. 

The Agency provides secretariat support for the API ADM Governance and APIO DG Committees.

Planning Highlights:

Working collaboratively with Health Canada, the Canadian Institutes for Health Research and the Canadian Food Inspection Agency in 2010-11, the Agency intends to expand upon previous activities in avian and pandemic influenza preparedness, through the continuation of the vaccine readiness strategies, antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. 

Federal Partner: The Agency

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Science and Technology for Public Health	a. Rapid vaccine development and testing	Ongoing	$1.6M	ER 1
	b. Winnipeg lab and space optimization	Ongoing	$20.2M	ER 2
Surveillance and Population Health Assessment	a. Surveillance	Ongoing	$8.3M	ER 3
Public Health Preparedness and Capacity	a. Vaccine readiness and clinical trials	Ongoing	$14.6M	ER 4.1  ER 4.2
	b. Capacity for pandemic preparedness	Ongoing	$5.8M	ER 5
	c. Emergency preparedness	Ongoing	$5.9M	ER 6.1  ER 6.2  ER 6.3  ER 6.4  ER 6.5  ER 6.6
	d. Emergency human resources	Ongoing	$0.4M	ER 7
	e. Strengthening the public health laboratory network	Ongoing	$1.2M	ER 8.1  ER 8.2  ER 8.3
	f. Influenza research network	Ongoing	$1.1M	ER 9
	g. Pandemic influenza risk assessment and modelling	Ongoing	$0.8M	ER 10.1  ER 10.2
	h. Performance and evaluation	Ongoing	$0.6M	ER 11.1  ER 11.2  ER 11.3
	i. Pandemic influenza risk communications strategy	Ongoing	$1.8M	ER 12.1  ER 12.2
	j. Skilled national public health workforce	Ongoing	$5.8M	ER 13.1  ER 13.2  ER 13.3  ER 13.4
Regulatory Enforcement and Emergency Response	a. Contribution to National Antiviral Stockpile	Ongoing	$0.1M	ER 14.1  ER 14.2
Total Agency			$68.2M

Expected results:

ER 1: Progress made on the development of different clinical-grade commercial H5N1 influenza vaccines.

ER 2: Renovation of the new lab is completed, thus increasing Canada's research and response capacity.

ER 3: Capacity to rapidly identify and report human cases of avian flu and health care incidents of potential significance is improved.

ER 4.1: Clinical trials of a pre-pandemic vaccine are underway, and the relevance of individual trials to Canada's needs is assessed.

ER 4.2: Capacity for vaccine-adverse event surveillance and effectiveness monitoring during a pandemic is improved.

ER 5: Capacity for increased use of the regional communication systems is improved.

ER 6.1: Response mechanisms  are established to respond to an avian or pandemic influenza outbreak.

ER 6.2: Laboratories are capable of working with certified influenza strains.

ER 6.3: Improved integration of quarantine stations with traditional services at the three major Canadian maritime ports.

ER 6.4: The National Emergency Stockpile System and the Emergency Operations Centres are maintained in a state of readiness.

ER 6.5: Incident response plans are in place with provincial and territorial departments and non-governmental organizations.

ER 6.6: Increased efficiency and effectiveness of regional resources placed to facilitate the flow of information between federal, provincial and territorial levels.

ER 7: An updated Human Resources Emergency Response Plan is in place.

ER 8.1: Federal laboratory liaison technicians in provinces and territories are in place, trained, and equipped.

ER 8.2: Communications between provincial and territorial labs and the National Microbiology Laboratory is improved thereby strengthening the national lab's capacity.

ER 8.3: Components of the Canadian Pandemic Influenza Plan's Annex C are in operation.

ER 9: Research resources are optimally allocated to respond to the needs of avian and pandemic influenza preparedness.

ER 10.1: Predictive and assessment models used for pandemic preparedness are developed and established.

ER 10.2: More potential learners in university and college settings are being trained as mathematical modelers to augment public health capacity in mathematical modeling.

ER 11.1: Evaluation improvements proposed in the Evaluation Plan for avian and pandemic influenza preparedness are implemented.

ER 11.2: Components of the performance measurement framework are in place at the responsibility-centre level.

ER 11.3: Performance data and evidence are collected using a Web-based system and are used for management and reporting.

ER 12.1: Social marketing needs are reviewed and appropriate modifications have been made in light of the H1N1 experience.

ER 12.2: A communications operational plan is developed to support the Canadian Pandemic Influenza Plan.

ER 13.1: Memorandums of understanding with selected placement sites for public health officers across the country are completed.

ER 13.2: An increased number of public health officers and Canadian Public Health Service regional coordinators are in place across Canada.

ER 13.3: An increased number of training modules are developed and delivered to public health officers in the field.

ER 13.4: Competency profiles for public health officers are developed.

ER 14.1: Improved lead time between the outbreak of a pandemic and the availability of a pandemic vaccine.

ER 14.2: The National Antiviral Stockpile is maintained and plans are established for the replacement of antiviral stocks as they reach the end of their shelf-life.

Federal Partner: HC

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Health Products	a. Regulatory activities related to pandemic influenza vaccine	Ongoing	$1.1 M	ER 15.1  ER 15.2  ER 15.3  ER 15.4  ER 15.5  ER 15.6
	b. Resources for review and approval of antiviral drug submissions for treatment of pandemic influenza	Ongoing	$0.2M	ER 16.1  ER 16.2  ER 16.3
	c. Establishment of a crisis risk management unit for monitoring and post-market assessment of therapeutic products	Ongoing	$0.3M	ER 17.1  ER 17.2
First Nations and Inuit health programming and services	a. FN/I surge capacity - FN/I Community Services	$1.5M (2007-08 to 2009-10)	No funding available	ER 18.1
	b. Strengthen federal public health capacity through Governance and Infrastructure Support to FN/I Health System	Ongoing	$0.7M	ER 19.1  ER 19.2  ER 19.3  ER 19.4  ER 19.5
	c. FN/I emergency preparedness, planning, training and integration	Ongoing	$0.3M	ER 20.1
Sustainable environmental health	a. Public health emergency preparedness and response (EPR) on conveyances	Ongoing	$0.2M	ER 21.1
Total HC			$2.8 M

Expected results:

ER 15.1: World Health Organization (WHO) Guidance on Regulatory Preparedness for Human Pandemic Influenza Vaccines.

ER 15.2: Finalize Extraordinary Use New Drugs (EUND) regulations.

ER 15.3: Continue links established with international regulatory bodies (WHO, Chinese SFDA) which increase the timeliness and availability of information in the event of a pandemic (i.e. pandemic influenza strain).

ER 15.4: Review response to the H1N1 events and produce lessons learned.

ER 15.5: Continue coordinating blood system preparedness through regular teleconferences and regulatory advice/decisions to CBS and HQ.  Our approaches have been shared with WHO Blood Regulator.

ER 15.6: Work with the WHO on recommendations for new pneumococcal conjugate vaccine through the WHO Expert Committee on Biologic Standardization.

ER 16.1: Complete review of any anti-viral submissions that may be received.

ER 16.2: Finalize “Expedited Pandemic Influenza Drug Review” (EPIDR) Protocol.

ER 16.3: Ongoing on-the-job reviewer training for the “accelerated review.” Review procedures for antivirals submissions, before and during pandemic occurrences are established.

ER 17.1: Maintenance of the crisis risk management unit.

ER 17.2: Ongoing post-market assessment of therapeutic products.

ER 18.1: Implementation of Pandemic and infection control education and training initiatives.

ER 19.1: Implement pandemic and infection control education and training initiatives.

ER 19.2: Collaborate with PHAC, PSC, and INAC for planning and response.

ER 19.3: Work on surveillance needs with PHAC.

ER 19.4: Enhance support for First Nations communities.

ER 19.5: Increase links with national and regional EPR program staff and with provinces and territories.

ER20.1: Continue to support the testing and revision of community pandemic plans.

ER21.1: Continue on-going program delivery, training and partnerships, program evaluations and adjustments to address findings.

Federal Partner: CIHR

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Pandemic Preparedness Research Strategic Initiative (PPSRI)	a. Influenza research priorities	$40.9 M (The end date of the PPSRI is March 31, 2011, however, additional partner funds are committed in 2011-12)	$11.0M	ER 22.1  ER 22.2  ER 22.3  ER 22.4
Total CIHR			$11.0 M

Expected results:

ER 22.1: Research projects are peer reviewed and funded.

ER 22.2: Requests for research applications are developed and launched as needed.

ER 22.3: Progress on funded projects and outcomes of research are reviewed.

ER 22.4: Uptake of research results is facilitated, and consultations on future research needs are completed through reports and meetings of researchers, stakeholders and decision makers.

Federal Partner: CFIA

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Zoonotic Risk	a. Enhanced enforcement measures	Ongoing	$1.5M	ER 1
	b. Avian biosecurity on farms	Ongoing	$2.7M	ER 2
	c. Real property requirements	$4.0M (2006-07 to 2007-08)	$0.0M	ER 3
	d. Domestic and wildlife surveillance	Ongoing	$3.1M	ER 4
	e. Strengthened economic and regulatory framework	Ongoing	$0.9M	ER 5
	f. Performance and evaluation	Ongoing	$1.2M	ER 6
	g. Risk communications	Ongoing	$1.6M	ER 7
	h. Field training	Ongoing	$1.1M	ER 8.1  ER 8.2
	i. AI enhanced management capacity	Ongoing	$1.0M	ER 9
	j. Updated emergency response plans	Ongoing	$2.0M	ER 10
	k. Risk assessment and modelling	Ongoing	$2.0M	ER 11
	l. AI Research	Ongoing	$1.5M	ER 12
	m. International collaboration	Ongoing	$1.6M	ER 13
	n. Animal vaccine bank	$0.9M (2006-07 to 2008-09)	$0.0M	ER 14
	o. Access to antivirals	Ongoing	$0.1M	ER 15
	p. Specialized equipment	$20.7M (2006-07 to 2008-09)	$0.0M	ER 16
	q. Laboratory surge capacity and capability	Ongoing	$3.7M	ER 17
	r. Field surge capacity	Ongoing	$1.0M	ER 18
	s. National veterinary reserve	Ongoing	$0.9M	ER 19
Total CFIA			$25.9M

Expected results:

ER 1: Increased capacity to support enhanced screening procedures for live birds or poultry products at Canada's ports of entry with a view to mitigating the risk of future avian influenza outbreaks in Canada.

ER 2: Continuation of stakeholder and general public education, communications and outreach programs in support of the implementation of the National Avian On Farm Biosecurity Standard. Provide stakeholder consultations and develop communication tools to expand education and awareness to the poultry industry service sector.

ER 3: No planned expenditures as investments were realized in previous fiscal years.

ER 4: Enhanced/integrated Canadian surveillance system, supported by a robust systems platform and the analysis and interpretation of the data collected to allow more timely identification of potential outbreaks, and more timely response to avian influenza situations. Targeted wild bird surveillance plan is yet to be determined for 2010.

ER 5: Initiatives to strengthen regulatory capacity during outbreaks, including a review and analysis of current legislative/regulatory framework continues.

ER 6: Management and evaluation of CFIA's AI activities, including ongoing performance measurement to monitor results.

ER 7: Continued implementation of the “Be Aware and Declare” international border biosecurity outreach campaign. Ongoing media monitoring and training and risk communications related to AI prevention, preparedness and response activities.

ER 8.1: Continued training that will contribute to a skilled and experienced workforce ready to respond to an AI outbreak.

 ER 8.2: Continued development of training materials (instructor-led and e-learning) in support of emergency response procedures and plans and of trainers in support of end-user training.

ER 9: A multi-disease version for the Canadian Emergency Management Response System (CEMRS) application for national surveillance/outbreak use will be available. Work on the next generation of the application will have begun.

ER 10: Continued development and updating of emergency response procedures and plans.

ER 11: Continued development of models to better understand the influence and interaction of various factors on the spread of AI and the effectiveness of the various methods used to control and eradicate the disease.

ER 12: Investment through research in an improved federal capacity for control, risk assessment, diagnostics and vaccines on avian influenza issues will allow a better understanding of the spread of influenza and the effectiveness of disease control measures. These investments will allow more timely and evidence-based decision making on avian influenza responses, thus helping to reducing the risk of transmission to humans and mitigating economic and production losses.

ER 13: CFIA staff continue to provide assistance to the World Organisation for Animal Health (OIE) Central Bureau in the Communications Department in an effort to promote the development and implementation of science based standards. Furthermore, the CFIA continues to support the OIE's mandate and efforts to assist member countries in the control and eradication of animal diseases, including zoonotics, through its annual contribution to the OIE. In addition, the CFIA continues to support the development of capacity to address emergence of risk at the animal level through the Canadian chapter of Veterinarians Without Borders.

ER 14: Future AI vaccines will be purchased on an “as need” basis.

ER 15: Maintenance of access protocols and bank of antivirals to provide appropriate protection to federal employees, ensuring a more timely and effective response to an avian influenza situation and better protection of Canadians.

ER 16: No planned expenditures as investments realized in previous fiscal years.

ER 17: Maintaining, coordinating and managing an integrated lab network (federal, provincial and university labs). This network allows for rapid testing, detection and reporting of AI.

ER 18: Continued development of a viable response plan, including HR capacity and data management  tools.

ER 19: Continued training of a reserve of professional veterinarians to enhance surge capacity, expertise and rapid response capability for animal disease control efforts.

Total Allocation For All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2010–11
$600M, including $405M for Health Portfolio and $195M for CFIA	$107.9M

Results to be achieved by non-federal partners (if applicable): N/A

Contact information:
Dr. John Spika
100 Eglantine Drive
Ottawa, ON K1A 0K9

Name of Horizontal Initiative: Canadian HIV Vaccine Initiative

Name of lead department(s): Public Health Agency of Canada (the Agency)

Lead department program activity: Disease and Injury Prevention and Mitigation

Start date of the Horizontal Initiative: February 20, 2007

End date of the Horizontal Initiative: March 2013

Total federal funding allocation (start to end date): $111M

Description of the Horizontal Initiative (including funding agreement):  The Canadian HIV Vaccine Initiative (CHVI) is a collaborative undertaking between the Government of Canada and the Bill & Melinda Gates Foundation to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration builds on the Government of Canada's commitment to a comprehensive, long-term approach to address HIV/AIDS. Participating federal departments and agencies are the Agency, Health Canada (HC), Industry Canada (IC), the Canadian International Development Agency (CIDA) and the Canadian Institutes of Health Research (CIHR). The CHVI's overall objectives are to: strengthen HIV vaccine discovery and social research capacity; strengthen clinical trial capacity and networks, particularly in low and middle income countries (LMICs); strengthen policy and regulatory approaches for HIV vaccines and promote the community and social aspects of HIV vaccine research and delivery; and ensure horizontal collaboration within the CHVI and with domestic and international stakeholders.

Shared outcome(s):

Immediate (Short-Term 1–3 years) Outcomes:

1. Increased and improved collaboration and networking.
2. Enhanced knowledge base.
3. Increased readiness and capacity in Canada and LMICs.

Intermediate Outcomes:

1. Strengthened contribution to global efforts to accelerate the development of safe effective, affordable, and globally accessible HIV vaccines. 

Long -Term Outcomes:

1. The Canadian HIV Vaccine Initiative contributes to the global efforts to reduce the spread of HIV/AIDS particularly in LMICs. 

Governance structure(s):

The Minister of Health, in consultation with the Minister of Industry and the Minister of International Cooperation, will be the lead Minister for the CHVI for the purpose of overall coordination. Communications for the CHVI will be handled jointly.

In support of the Ministers, coordination for the Government of Canada is provided by an Interdepartmental Steering Committee consisting of representatives from the participating federal departments and agencies. The Committee is responsible for providing strategic directions and setting priorities and reviewing progress.

Multi-stakeholder advisory committees and working groups, involving governments, the private sector, international stakeholders, people living with HIV/AIDS, researchers and non-governmental organizations and other relevant stakeholders, have been, and will continue to be established to inform the CHVI.

Planning Highlights:

CHVI-participating departments and agencies will continue to implement activities initiated in 2009-10. For example, approved community-based initiatives and research projects will continue to be supported. New activities planned for 2010-11 include the launch of the Discovery and Social Research Large Team Grants Funding Opportunity. The Government of Canada and the Gates Foundation will work together to define areas of investment to accelerate the development of a safe, effective, affordable and accessible HIV vaccine as one of our key priorities.

Federal Partner: The Agency

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Disease and Injury Prevention and Mitigation	Infectious Disease Prevention and Control	$6.5M	$1.2M	ER 1
		$17.0M	$8.7M	ER 2
		$3.5M	$10.7	ER 3
Total Agency		$27.0M	$10,661M

Expected results:

ER 1: New vaccine policy approaches and increased community involvement (in partnership with Health Canada).

ER 2: New areas of investment defined.

ER 3: Effective horizontal coordination and communications with stakeholder groups through secretariat support services provided to CHVI committees, CHVI website and day-to-day communications.

Federal Partner: HC

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
International Health Affairs	International Health Grants Program	$1M	$0	ER 1
Total HC		$1M	$0

Expected results:

ER 1: New vaccine policy approaches and increased community involvement (in partnership with the Agency).

Federal Partner: IC

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Industry Sector- Science and Technology and Innovation	N/A	$13M	$1.5M	ER 1
Total IC		$13M	$3.3M

Expected results:

ER 1: New areas of investment defined.

Federal Partner: CIDA

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
Enhanced capacity and effectiveness of multilateral institutions, Canadian and international organizations in achieving development goals	International Development Assistance Program	$16M	$3.5M	ER 1
		$12M		ER 2
		$30M	$12.3M	ER 3
		$2M	$0.5M	ER 4
Total CIDA		$60M	$16.3M

Expected results:

ER 1: Increased capacity to conduct high-quality clinical trials of HIV vaccine and other related prevention technologies in LMICs through new teams of Canadian and LMICs researchers and research institutions.

ER 2: In collaboration with CIHR, increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through the successful completion of the development stage of the Team Grant program to support collaborative teams of Canadian and LMIC researchers.

ER 3: New areas of investment defined.

ER 4: Increased capacity of regulatory authorities in LMICs especially those where clinical trials are planned or ongoing, through training and networking initiatives.

Federal Partner: CIHR

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2010-11	Expected Results for 2010-11
HIV/AIDS Research Initiative	HIV/AIDS Research Initiative	$10M	$1.2M	ER 1
Total CIHR		$10M	$1.2M

Expected results:

ER 1: Increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through:

1. ongoing support for operating and catalyst grants undertaken by Canadian researchers;
2. commencement of funding for two emerging teams of Canadian researchers; and
3. completion of the development stage of the Large Team Grant program to support collaborative teams of Canadian and LMIC researchers in collaboration with CIDA.

Total Allocation For All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2010–11
$111M	$31.3M

Results to be achieved by non-federal partners (if applicable):  N/A

Non-governmental stakeholders (including research institutions and not-for-profit community organizations) are integral to the success of the CHVI. Their role is to engage and collaborate with participating departments and agencies, the Bill and Melinda Gates Foundation and other funding agencies to contribute to CHVI objectives and to a significant Canadian contribution towards the Global HIV Vaccine Enterprise.

Contact information:
Steven Sternthal
200 Eglantine Driveway
Ottawa, Ontario  K1A 0K9